logo
Plus   Neg
Share
Email

Kier Group Says Trading In Line With View; COO Claudio Veritiero Resigns

Construction, services and property group Kier Group Plc (KIE.L) Friday said it is trading in line with the Board's expectations.

Further, the company said Chief Operating Officer Claudio Veritiero will stand down from the Board and leave the business with immediate effect. The COO responsibilities will be assumed by the Chief Executive and the Chief Financial Officer.

The company also noted that Adam Walker, who joined the Board on January 1, 2016, has informed the Board of his intention to step down from the Board with effect from December 31.

Justin Atkinson, the Senior Independent Non-Executive Director, will then assume the role of Chair of the Risk Management and Audit Committee until a successor to Walker has been appointed.

The process to appoint a new Chairman is ongoing.

In its Annual General Meeting trading update, the company said it has received about 1 billion pounds of new contracts since June 30. The company has been appointed to a number of frameworks, including the 30 billion pounds Construction Works and Associated Services framework for the Crown Commercial Service.

Further, the company continues to focus on operational cash generation, with working capital and net debt both in line with the Board's expectations.

Kier Group added that it remains on course to deliver a headcount reduction of about 1,200 by June 30, 2020 and annual cost savings of at least 55 million pounds in the financial year ending June 30, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
New York Attorney General Letitia James has fled a lawsuit against Vyera Pharmaceuticals and two of its former CEOs, including imprisoned 'Pharma Bro' Martin Shkreli, for illegally monopolizing a life-saving drug Daraprim. The lawsuit seeks a lifetime ban on Shkreli and his business partner Kevin Mulleady working in the pharmaceutical industry. Graco Inc. (GGG) shares were climbing more than 7 percent in morning trade. Monday after market close, the company had reported a surge in the fourth-quarter earnings to $84.8 million from $73.7 million in the prior year. Earnings per share surpassed analysts' estimates. Sales were up 1 percent to $412.3... Strategy of getting multiple indication approvals for the same drug seems to be paying off for AstraZeneca PLC (AZN), in terms of higher likelihood of approval and improved sales. Besides, the company is realizing value from non-core, mature brands to invest in new drugs, which also seems to be working in its favor.
RELATED NEWS
Follow RTT
>